1. Beohar N, Davidson CJ, Kip KE, Goodreau L, Vlachos HA, Meyers SN, Benzuly KH, Flaherty JD, Ricciardi MJ, Bennett CL, Williams DO. Outcomes and complications associated with off-label and untested use of drug-eluting stents. Jama 297(18), 1992–2000 (2007).
2. FDA. Summary from the Circulatory system Devices Panel Meeting – December 7 & 8, 2006. https://www.fda.gov/ohrms/dockets/ac/06/minutes/2006-4253m2-%20Final%201208summ.pdf , last assessed 2017/12/12.
3. Macku D. The Continuous Flow Total Artificial Heart in Clinical Practice. In: World Congress on Medical Physics and Biomedical Engineering, June 7–12, 2015, Toronto, Canada. Springer International Publishing, 2015. p. 318–321.
4. Shekar K, Gregory SD, Fraser JF. Mechanical circulatory support in the new era: an overview. Critical Care. 2016;20(1):66.
5. Cohn WE, Timms DL, Frazier OH. Total artificial hearts: past, present, and future. Nature Reviews Cardiology. 2015;12(10):609–617.